<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology and clinical manifestations of invasive aspergillosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology and clinical manifestations of invasive aspergillosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology and clinical manifestations of invasive aspergillosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas F Patterson, MD, FACP, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term "aspergillosis" refers to illness due to allergy, airway or lung invasion, cutaneous infection, or extrapulmonary dissemination caused by species of <em>Aspergillus</em>, most commonly <em>A. fumigatus</em>, <em>A. flavus</em>, <em>A. niger, </em>and <em>A. terreus</em>. <em>Aspergillus </em>species are ubiquitous in nature, and inhalation of infectious conidia is a frequent event. Tissue invasion is uncommon and occurs most frequently in the setting of immunosuppression associated with therapy for hematologic malignancies, hematopoietic cell transplantation, or solid organ transplantation.</p><p>The pathogenesis, epidemiology, clinical manifestations, and differential diagnosis of invasive aspergillosis will be reviewed here. The diagnosis and treatment of invasive aspergillosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/d/html/2419.html" rel="external">"Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"</a> and  <a class="medical medical_review" href="/d/html/2441.html" rel="external">"Chronic pulmonary aspergillosis: Epidemiology, clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2440.html" rel="external">"Chronic pulmonary aspergillosis: Treatment"</a>.)</p><p class="headingAnchor" id="H625354394"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Inhaled conidia are met by the innate defenses provided by resident phagocytes, specifically airway epithelial cells and alveolar macrophages [<a href="#rid1">1,2</a>]. Little is known about the contribution of epithelial cells in clearing conidia. Relatively more is known about macrophages, which contribute to both conidial clearance and the production of secondary inflammation. These cells secrete inflammatory mediators after recognition of key cell wall components (eg, beta-D-glucan) exposed after conidial germination into hyphal forms. These mediators result in neutrophil recruitment and the activation of cellular immunity, which are important in killing potentially invasive microbial forms (hyphae) and determining the extent and nature of the immune response. Hence, risks for disease and the type of disease that occurs are the combined result of multiple cellular functions that impact proximal events in conidial clearance, production of inflammation, and killing of invasive forms [<a href="#rid1">1</a>].</p><p>Microbial factors that impact disease potential include toxins, proteases, and secondary metabolites that exert multiple effects on the host's local pulmonary and systemic defense. These include cellular products that:</p><p class="bulletIndent1"><span class="glyph">●</span>Inhibit phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, a key component in host defense against filamentous fungi</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhibit macrophage phagocytosis and killing</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suppress functional T cell responses</p><p></p><p>Histopathologically, invasive aspergillosis is characterized by progression of the infection across tissue planes. One hallmark of infection is vascular invasion with subsequent infarction and tissue necrosis. Presumably, fungal cell surface components bind to vessel wall components, including basement membrane, extracellular matrix, and cellular constituents, and can cause ischemia and infarction of structures distal to invaded arteries.</p><p class="headingAnchor" id="H2"><span class="h1">MICROBIAL EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H429408"><span class="h2">Classification</span><span class="headingEndMark"> — </span>In the past, mycologists utilized phenotypic characteristics to identify <em>Aspergillus</em> organisms to the species level; however, some species are not distinguishable based on phenotypic typing. Use of molecular methods has expanded the number of recognized species and increased our knowledge of the organism's pathogenicity and other characteristics [<a href="#rid3">3</a>].</p><p>Given the complexity of the classification scheme and lack of routine molecular typing, it has been suggested that isolates be referred to as being members of a "species complex."</p><p class="headingAnchor" id="H429415"><span class="h2">Species prevalence</span><span class="headingEndMark"> — </span>Most invasive infections are caused by members of the <em>A. fumigatus</em> species complex. In a report of 218 infections in 24 transplant centers in the United States, 67 percent were caused by members of the <em>A. fumigatus</em> complex, followed by <em>A. flavus</em> (13 percent), <em>A. niger</em> (9 percent), and <em>A. terreus</em> (7 percent). These data contrast with epidemiologic data from a decade earlier when the vast majority of cases (90 percent) were secondary to <em>A. fumigatus</em> species [<a href="#rid4">4</a>], likely reflecting changes in microbial epidemiology, center-based differences, and/or changes in typing methods.</p><p class="headingAnchor" id="H4"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Underlying conditions that compromise pulmonary and systemic immune responses to inhaled <em>Aspergillus</em> species serve as risk factors for invasive disease.</p><p>Classic risk factors include:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe and prolonged neutropenia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Receipt of high doses of glucocorticoids</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other drugs or conditions that lead to chronically impaired cellular immune responses (eg, immunosuppressive regimens administered to treat autoimmune diseases and to prevent organ rejection, AIDS)</p><p></p><p>Use of certain biologic agents (eg, Bruton’s tyrosine kinase inhibitors [<a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>], small molecule kinase inhibitors) also raise the invasive aspergillosis [<a href="#rid5">5,6</a>]. Other agents such as <a class="drug drug_general" data-topicid="107696" href="/d/drug information/107696.html" rel="external">venetoclax</a>, a B-cell leukemia/lymphoma-2 inhibitor used in hematologic malignancies, may increase risk for invasive aspergillosis although venetoclax is often used in combination with other chemotherapeutic agents like <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> so that individual risk is unclear [<a href="#rid7">7</a>]. A large number of novel agents impacting numerous immunologic pathways are widely used. Many of these agents have theoretic risks for invasive aspergillosis, which should be considered in patients being evaluated for invasive aspergillosis [<a href="#rid8">8</a>]. </p><p>Specific risk factors in certain immunocompromised patients include:</p><p class="bulletIndent1"><span class="glyph">●</span>In hematopoietic cell transplant (HCT) recipients, risks are different early versus late after receipt of stem cells. Underlying disease, persistent neutropenia, and types of stem cells and conditioning impact risks early after transplant. Additional risk factors during the latter period include graft-versus-host disease (and accompanying therapies) and cytomegalovirus (CMV) infection and disease [<a href="#rid9">9</a>]. Immunologic variables that correlate with risk include impaired production of reactive oxygen species and qualitative and quantitative defects in NK and T cells [<a href="#rid10">10-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Various gene polymorphisms (in HCT donors, HCT and solid organ transplant recipients, or patients with hematologic malignancies) have been associated with an increased risk of invasive aspergillosis. Examples include polymorphisms in genes involved in the innate immune response, such as the toll-like receptor 4 gene [<a href="#rid13">13</a>], interleukin 1 beta and beta-defensin 1 [<a href="#rid14">14</a>], the soluble pattern recognition receptor, long pentraxin 3 [<a href="#rid15">15,16</a>], dectin-1 [<a href="#rid17">17,18</a>], and others [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Airway colonization in lung transplant recipients with cystic fibrosis is a risk factor for disease following transplantation [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/d/html/1394.html" rel="external">"Fungal infections following lung transplantation", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In liver transplant recipients, increasing immunosuppression, hemodialysis, and CMV infection are risks factors [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In renal transplant recipients, a longer duration of hemodialysis before transplantation and leukopenia are risk factors for early-onset infection (≤3 months following transplantation) [<a href="#rid23">23</a>]. Donor CMV seropositivity is a risk factor for late-onset infection (&gt;3 months following transplantation).</p><p></p><p>Emerging risk factors described patients with no or milder immunosuppression include:</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic obstructive pulmonary disease, with receipt of glucocorticoid therapy [<a href="#rid24">24</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intensive care unit (ICU) admission [<a href="#rid25">25-27</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Certain viral infections (eg, influenza, severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], respiratory syncytial virus) [<a href="#rid26">26,28-30</a>] </p><p></p><p>Invasive aspergillosis associated with viral infections typically occurs in patient with respiratory failure in ICUs. In these settings, invasive aspergillosis is thought to occur secondary to epithelial airway injury facilitating <em>Aspergillus </em>colonization and invasion. Influenza-associated aspergillosis (IAA) was evaluated over a seven-year period in Belgian and Dutch ICUs; among patients who had influenza pneumonia admitted to ICUs, 19 percent developed invasive aspergillosis. Forty-four percent lacked classic risk factors [<a href="#rid31">31</a>]. Mortality of IAA was 51 percent compared with 28 percent in patients with influenza alone.</p><p>SARS-CoV-2 (COVID-19) has also been associated with pulmonary aspergillosis in multiple case series [<a href="#rid28">28,32-38</a>]. The reported incidence varies widely across studies (0 to 33 percent) [<a href="#rid34">34</a>]. This wide range may in part be due to the difficulty of distinguishing airway colonization from invasive infection and varied diagnostic criteria. When relying on strict criteria for diagnosis (including autopsy data), the incidence appears to be approximately 2 to 6 percent [<a href="#rid35">35,39</a>]. Among reported cases, age &gt;65 years, chronic structural lung disease, receipt of immunomodulatory agents, immunocompromising conditions, and invasive ventilatory support appear to be the most significant risk factors for its acquisition [<a href="#rid32">32-35,40-42</a>]. Extensive use of corticosteroids or receipt of <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a> or other interleukin-6 inhibitors or Janus kinase/signal transducer and activator of transcription inhibitors, such as <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a>, may also increase the risk [<a href="#rid28">28,42</a>].</p><p>The nature of the immune suppression, including degree, duration, and type of immunocompromise and concomitant therapy influences the pathogenesis of disease. Thus, invasive aspergillosis can be manifested as a spectrum of diseases involving predominantly the airways (eg, tracheobronchitis), the lung, or both and also as disseminated disease, involving the central nervous system and other organs.</p><p>Invasive disease is most frequent when there is a high amount of airway exposure, for instance, in the setting of construction [<a href="#rid43">43</a>] or when the host has a condition in which conidia are not effectively cleared. Historically, the highest risks for invasive infections have been seen in severely immunosuppressed patients, particularly allogeneic HCT recipients, solid organ transplant (especially lung, heart-lung, and liver) recipients, and patients who experience prolonged neutropenia. There are some inherited immunodeficiencies, such as chronic granulomatous disease, that lead to high risk for pulmonary aspergillosis [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Invasive aspergillosis most frequently occurs in the lungs or sinuses after inhalation of conidia, although, less commonly, disease can spread from the gastrointestinal tract or result from direct inoculation into the skin.</p><p class="headingAnchor" id="H6"><span class="h2">Pulmonary aspergillosis</span><span class="headingEndMark"> — </span>Invasive aspergillosis most commonly involves the lungs  (<a class="graphic graphic_picture graphicRef57220" href="/d/graphic/57220.html" rel="external">picture 1</a>). Patients can present with a number of signs and symptoms: fever, chest pain, shortness of breath, cough, and/or hemoptysis. The classic triad that has been described in neutropenic patients with pulmonary aspergillosis is fever, pleuritic chest pain, and hemoptysis. However, absence of this triad should not discourage consideration of this diagnosis in the patient with risk factors for disease since neutropenic patients frequently present with fever in the absence of localizing pulmonary symptoms. In such patients, lung imaging often reveals pulmonary nodules and/or infiltrates.</p><p class="headingAnchor" id="H429431"><span class="h3">Imaging</span><span class="headingEndMark"> — </span>Chest radiograph is insensitive for detecting the earliest stages of pulmonary disease, but computed tomography (CT) scans typically demonstrate focal lesions  (<a class="graphic graphic_diagnosticimage graphicRef56195" href="/d/graphic/56195.html" rel="external">image 1</a>). The type of radiographic abnormality is variable, depending upon the host and the type of disease: bronchopneumonia, angioinvasive aspergillosis, tracheobronchitis, or chronic necrotizing aspergillosis.</p><p>Pulmonary aspergillosis typically manifests as single or multiple nodules (with or without cavitation), patchy or segmental consolidation, or peribronchial infiltrates with or without tree-in-bud patterns. One relatively large review noted that small nodules (&lt;1 cm) were most common (20 of 46; 43 percent), followed by consolidation (12 of 46; 26 percent), large nodules (masses, 10 of 46; 21 percent), and peribronchial infiltrates (4 of 46; 9 percent) [<a href="#rid44">44</a>]. Another large study that included neutropenic and nonneutropenic patients showed that the more specific signs (nodules and cavitation) were infrequent, and radiographic findings of consolidation, ground-glass infiltrates, and pleural effusions were more commonly seen [<a href="#rid45">45</a>].</p><p>Radiographic findings, as with disease manifestations, can be variable and largely depend upon the host. The radiographic progression of disease has been studied best in neutropenic patients in whom the initial findings typically include nodules that have surrounding ground-glass infiltrates (the halo sign), reflecting hemorrhage into the area surrounding the fungus  (<a class="graphic graphic_diagnosticimage graphicRef56195" href="/d/graphic/56195.html" rel="external">image 1</a>) [<a href="#rid46">46</a>]. These nodules typically enlarge, even during appropriate therapy, and may eventually cavitate, producing the air-crescent sign [<a href="#rid47">47,48</a>].</p><p>However, in one study, it was noted that neutropenic patients more frequently presented with segmental areas of consolidation rather than demonstrating the classic nodule progression to cavitation  (<a class="graphic graphic_diagnosticimage graphicRef70038" href="/d/graphic/70038.html" rel="external">image 2</a>) [<a href="#rid45">45</a>]. Similar findings were reported in a cohort of solid organ transplant recipients, with the majority of patients presenting with "pulmonary pneumonia" (focal infiltrates, 39 percent) or "pulmonary nodular" (21 percent) findings on CT scan [<a href="#rid49">49</a>]. In a cohort of 139 children, the most common radiographic presentation was nodules (35 percent); few children developed cavitary disease (2 percent) [<a href="#rid50">50</a>].</p><p>There may be a role for CT pulmonary angiography for distinguishing between invasive mold infections and other causes of pulmonary infiltrates, by virtue of detection of angioinvasion [<a href="#rid51">51,52</a>]. However, the studies that evaluated this modality were small and did not evaluate patients with a heterogeneous group of underlying diseases. In addition, the risk of nephrotoxicity associated with the use of intravenous (IV) contrast has not been adequately evaluated. Larger studies will be needed to define the role of CT pulmonary angiography for diagnosing invasive aspergillosis.</p><p class="headingAnchor" id="H2602743940"><span class="h2">COVID-19-associated infection</span><span class="headingEndMark"> — </span>Clinical features associated with pulmonary aspergillosis in patients with coronavirus disease 2019 (COVID-19) vary considerably. Most reported cases have occurred in patients who are critically ill and/or mechanically ventilated [<a href="#rid38">38,53,54</a>]. In one case series of 20 patients, pulmonary aspergillosis was diagnosed a median of 11 days after symptom onset of COVID-19 and 9 days after intensive care unit admission [<a href="#rid55">55</a>]. Radiographic findings included ground glass opacities, consolidation, bronchiectasis, and in some cases, nodules and cavities. These findings likely reflect both viral pneumonia, and the array of findings due to aspergillosis, ranging from early airway inflammation, to invasive pneumonia with necrotic cavitary disease. </p><p>Because clinical features of COVID-19 and pulmonary aspergillosis vary and overlap, diagnosis is challenging [<a href="#rid34">34,37</a>]. In general, suspicion for invasive aspergillosis should be raised in any patient with COVID-19 with radiographic features suggestive of invasive aspergillosis (ie, multiple nodules or cavitary disease). Because patients with severe COVID-19 often have marked bilateral ground glass opacities, typical findings can be obscured; thus, suspicion should also be raised in patients with prolonged or relapsing respiratory failure, particularly in those with structural lung disease, age &gt;65 years, and/or immunocompromising conditions [<a href="#rid28">28</a>].</p><p>Our approach to diagnosis and treatment is discussed separately. (See  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a>.)</p><p class="headingAnchor" id="H625354412"><span class="h2">Tracheobronchitis</span><span class="headingEndMark"> — </span><em>Aspergillus</em> tracheobronchitis has been reported most commonly in lung transplant recipients but has also been described in other types of hosts (eg, recipients of other solid organ transplants, patients with hematologic malignancies, patients with HIV infection) [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/1394.html" rel="external">"Fungal infections following lung transplantation", section on 'Tracheobronchial aspergillosis'</a>.)</p><p>Affected patients typically present with prominent dyspnea, cough, and wheezing; they occasionally expectorate intraluminal mucus plugs. Chest imaging may be normal or reveal areas of airway thickening, patchy infiltrates, consolidation, or centrilobular nodules.</p><p>Different patterns of <em>Aspergillus</em> tracheobronchitis have been described:</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive bronchial aspergillosis, a condition in which thick mucus plugs filled with <em>Aspergillus</em> hyphae are found in the airways, with little mucosal inflammation or invasion</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ulcerative tracheobronchitis, in which there is focal invasion of the tracheobronchial mucosa and/or cartilage by fungal hyphae</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pseudomembranous tracheobronchitis, which is characterized by extensive inflammation and invasion of the tracheobronchial tree with a pseudomembrane composed of necrotic debris and <em>Aspergillus</em> hyphae overlying the mucosa</p><p></p><p>Lung transplant recipients can also develop aspergillosis of the bronchial stump. This complication results from infection of the suture material and its incidence can be reduced with the use of nylon monofilaments rather than silk sutures. Patients complain of cough and may have hemoptysis.</p><p>Tracheobronchial disease can also occur in other hosts, including those who have hematologic malignancies, hematopoietic cell transplantation [<a href="#rid57">57</a>], and chronic obstructive pulmonary disease.</p><p class="headingAnchor" id="H7"><span class="h2">Chronic necrotizing and chronic cavitary pulmonary aspergillosis</span><span class="headingEndMark"> — </span>Patients who have underlying chronic lung disease are at risk for indolent forms of pulmonary aspergillosis, characterized by cavities or infiltrates that may or may not demonstrate hyphal invasion of tissue on histopathology. Presumably, the slowly progressive nature of this infection is a function of the host immune response, which is enough to hold the organism in check but not to eliminate it. Cough, weight loss, fatigue, and chest pain are common, and the chest radiograph shows a slowly progressive lesion, which can be better defined by CT scanning. However, interpretation of radiologic studies may be complicated by the presence of concomitant lung disease, since this is the setting in which chronic aspergillosis usually occurs. (See  <a class="medical medical_review" href="/d/html/2441.html" rel="external">"Chronic pulmonary aspergillosis: Epidemiology, clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H58499421"><span class="h2">Disseminated infection</span><span class="headingEndMark"> — </span>In the presence of angioinvasive disease, <em>Aspergillus</em> spp can disseminate beyond the respiratory tract to multiple different organs, including the skin, brain, eyes, liver, and kidneys. Disseminated infection is associated with a very poor prognosis. (See  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Prognostic factors'</a>.)</p><p class="headingAnchor" id="H625354431"><span class="h2">Rhinosinusitis</span><span class="headingEndMark"> — </span>In the paranasal sinuses, aspergillosis can present in an identical fashion to mucormycosis. However, rhinocerebral aspergillosis is usually seen in neutropenic patients with hematologic malignancy, whereas mucormycosis occurs most commonly in those with diabetes mellitus or hematologic malignancy. (See  <a class="medical medical_review" href="/d/html/2452.html" rel="external">"Fungal rhinosinusitis"</a>.)</p><p>The inflammatory response to the infection may be blunted because of neutropenia, and findings may be subtle. Nevertheless, nasal congestion, fever, and pain in the face and around the eye are common presenting features. If the orbit becomes involved, additional symptoms may include blurred vision, proptosis, and chemosis. The infection can also extend locally into the vasculature and the brain, leading to cavernous sinus thrombosis and a variety of central nervous system (CNS) manifestations.</p><p>CT findings may be subtle and can include focal soft tissue lesions, subtle focal bony erosions, and focal hypodense areas; magnetic resonance imaging (MRI) may also show soft tissue lesions as well as focal enhancement of the sinus lining [<a href="#rid58">58</a>].</p><p>Biopsy is necessary to establish the diagnosis; multiple biopsies are sometimes necessary [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis", section on 'Culture'</a> and  <a class="medical medical_review" href="/d/html/2452.html" rel="external">"Fungal rhinosinusitis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3038609"><span class="h2">Central nervous system infection</span><span class="headingEndMark"> — </span>CNS aspergillosis may occur in the setting of disseminated infection as well as from local extension from the paranasal sinuses. Patients with CNS involvement with <em>Aspergillus</em> spp may present with seizures or focal neurologic signs [<a href="#rid1">1</a>]. Mycotic aneurysms develop in some cases and can rupture, resulting in a hemorrhagic cerebrovascular accident, subarachnoid hemorrhage, and/or empyema formation [<a href="#rid59">59</a>].</p><p>In a study of the CT and/or MRI findings associated with CNS aspergillosis, three patterns were observed [<a href="#rid60">60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Ring-enhancing lesions consistent with brain abscesses  (<a class="graphic graphic_diagnosticimage graphicRef71228" href="/d/graphic/71228.html" rel="external">image 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral cortical and subcortical infarction with or without superimposed hematomas  (<a class="graphic graphic_diagnosticimage graphicRef50013" href="/d/graphic/50013.html" rel="external">image 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mucosal thickening of a paranasal sinus with secondary intracranial dural enhancement consistent with direct extension from the sinuses  (<a class="graphic graphic_diagnosticimage graphicRef66095" href="/d/graphic/66095.html" rel="external">image 5</a>)</p><p></p><p>CNS infection is associated with a very poor prognosis. (See  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Prognostic factors'</a>.)</p><p class="headingAnchor" id="H625354444"><span class="h2">Endophthalmitis</span><span class="headingEndMark"> — </span><em>Aspergillus</em> endophthalmitis may be a presenting feature of disseminated aspergillosis, in which involvement of the deep structures of the eye results not only from hematogenous spread. In other patients, corneal infection or direct inoculation following trauma is the genesis of infection [<a href="#rid61">61</a>]. Patients present with eye pain and visual changes [<a href="#rid62">62</a>].</p><p>Progressive infection is characterized by destruction of multiple components of the eye. The outcome is usually poor with loss of useful vision in the affected eye and a requirement for enucleation in some cases. (See  <a class="medical medical_review" href="/d/html/16205.html" rel="external">"Treatment of endophthalmitis due to molds", section on 'Introduction'</a>.)</p><p class="headingAnchor" id="H625354461"><span class="h2">Endocarditis</span><span class="headingEndMark"> — </span><em>Aspergillus</em> spp are second only to <em>Candida</em> spp as a cause of fungal endocarditis [<a href="#rid63">63</a>]. This infection occurs primarily in patients with prosthetic heart valves. In many patients, infection occurs at the time of surgery, with the fungus contaminating the surgical site. Patients may present at any time postoperatively. (See  <a class="medical medical_review" href="/d/html/8121.html" rel="external">"Mechanical prosthetic valve thrombosis or obstruction: Clinical manifestations and diagnosis"</a>.)</p><p>Other patients at risk for the development of <em>Aspergillus</em> endocarditis include patients with indwelling central venous catheters and people who inject intravenous drugs.</p><p>Patients typically present with fever and embolic phenomena. Blood cultures are rarely positive, even when a fungal isolator system is used. Microscopic examination of an embolus will reveal the typical hyphae suggestive of aspergillosis, but definitive microbiologic diagnosis depends upon culture of the organism. (See  <a class="medical medical_review" href="/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis", section on 'Culture'</a>.)</p><p>The prognosis of <em>Aspergillus</em> endocarditis is poor. Even with combined medical and surgical therapy, the mortality rate has approached 100 percent [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis", section on 'Prognostic factors'</a>.)</p><p class="headingAnchor" id="H625354468"><span class="h2">Cutaneous aspergillosis</span><span class="headingEndMark"> — </span>Cutaneous aspergillosis can be either primary, occurring from direct inoculation, usually in the presence of trauma, or secondary, occurring from contiguous extension or bloodborne spread  (<a class="graphic graphic_picture graphicRef61124" href="/d/graphic/61124.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef107468" href="/d/graphic/107468.html" rel="external">picture 3</a>) [<a href="#rid65">65</a>].</p><p>A review noted that otherwise healthy hosts can develop cutaneous disease in surgical wounds or by traumatic inoculation, especially when this occurs in the presence of high spore counts, such as might occur during a farming accident [<a href="#rid65">65</a>]. While burn victims, neonates, and solid organ transplant recipients tend to develop primary cutaneous disease in the presence of prolonged local skin injury, patients with hematologic malignancies and hematopoietic cell transplant recipients more frequently develop disease due to contiguous or hematogenous spread to the skin.</p><p>Diagnosis can only be verified by skin biopsy, which should be taken from the center of the lesion and reach the subcutaneous fat in order to visualize hyphae invading blood vessels of the dermis and subcutis [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis", section on 'Culture'</a>.)</p><p class="headingAnchor" id="H625354475"><span class="h2">Gastrointestinal aspergillosis</span><span class="headingEndMark"> — </span>Aspergillosis can involve the gastrointestinal (GI) tract, causing focal invasion as a primary site of inoculation and presenting as neutropenic enterocolitis (typhlitis), appendicitis, colonic ulcers, abdominal pain, and/or GI bleeding [<a href="#rid66">66-68</a>]. Direct inoculation from the GI tract is likely, with risk factors including neutropenia, receipt of glucocorticoids, and mucosal breakdown (mucositis).</p><p class="headingAnchor" id="H250762355"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Several fungi can cause invasive infections that are indistinguishable from invasive aspergillosis on clinical or radiographic grounds alone. Furthermore, the risk factors for invasive aspergillosis are similar to those for other invasive fungal infections. It is important to establish a microbiologic diagnosis since the treatment regimen depends upon the species isolated. (See  <a class="medical medical_review" href="/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis"</a>.)</p><p>Fungi that can cause invasive pulmonary infections with clinical and radiographic features (eg, halo sign) that are similar to those caused by <em>Aspergillus</em> spp include:</p><p class="bulletIndent1"><span class="glyph">●</span>Mucorales (see  <a class="medical medical_review" href="/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Fusarium</em> spp (see  <a class="medical medical_review" href="/d/html/2426.html" rel="external">"Mycology, pathogenesis, and epidemiology of Fusarium infection"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Scedosporium apiospermum</em> complex (see  <a class="medical medical_review" href="/d/html/2424.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Scedosporium and Lomentospora infections"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Lomentospora prolificans</em> (formerly <em>Scedosporium prolificans</em>) (see  <a class="medical medical_review" href="/d/html/2424.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Scedosporium and Lomentospora infections"</a>)</p><p></p><p>The halo sign can also be seen with other fungal infections and <em>Pseudomonas aeruginosa</em> infections [<a href="#rid1">1</a>]. (See <a class="local">'Imaging'</a> above.)</p><p>Imaging findings of invasive pulmonary aspergillosis can also overlap with those of tuberculosis [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/7026.html" rel="external">"Pulmonary tuberculosis: Clinical manifestations and complications", section on 'Radiologic findings'</a>.)</p><p>Mucormycosis can also cause rhinosinusitis with extension into the central nervous system that is clinically and radiographically similar to invasive aspergillosis. However, rhinocerebral aspergillosis is usually seen in neutropenic patients with hematologic malignancy, whereas mucormycosis also occurs in those with diabetes mellitus. (See  <a class="medical medical_review" href="/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p>In addition to <em>Aspergillus</em> spp, brain abscesses can be caused by a variety of fungi including the Mucorales, <em>Fusarium</em> spp, <em>Scedosporium</em> spp, and dematiaceous fungi. (See  <a class="medical medical_review" href="/d/html/2417.html" rel="external">"Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)"</a> and  <a class="medical medical_review" href="/d/html/1297.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of brain abscess"</a>.)</p><p class="headingAnchor" id="H2512715969"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109727.html" rel="external">"Society guideline links: Aspergillosis"</a>.)</p><p class="headingAnchor" id="H93589323"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83434.html" rel="external">"Patient education: Invasive aspergillosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1016797"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> − The term "aspergillosis" refers to illness due to allergy, airway or lung invasion, cutaneous infection, or extrapulmonary dissemination caused by species of <em>Aspergillus</em>. <em>Aspergillus</em> species are ubiquitous in nature, and inhalation of infectious conidia is a frequent event. Tissue invasion is uncommon and occurs most frequently in the setting of immunosuppression associated with therapy for hematologic malignancies, hematopoietic cell transplantation, or solid organ transplantation. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> − Inhaled conidia are met by the innate defenses provided by resident phagocytes, specifically airway epithelial cells and alveolar macrophages. Macrophages secrete inflammatory mediators after recognition of key cell wall components (eg, beta-D-glucan) exposed after conidial germination into hyphal forms. These mediators result in neutrophil recruitment and the activation of cellular immunity, which are important in killing potentially invasive microbial forms (hyphae) and determining the extent and nature of the immune response. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> − Invasive aspergillosis is characterized by progression of the infection across tissue planes. One hallmark of infection is vascular invasion with subsequent infarction and tissue necrosis. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspergillus species</strong> − Most invasive infections are caused by members of the <em>A. fumigatus</em> species complex. In a report of 218 infections in the United States, 67 percent were caused by members of the <em>A. fumigatus</em> complex, followed by <em>A. flavus</em> (13 percent), <em>A. niger</em> (9 percent), and <em>A. terreus</em> (7 percent). (See <a class="local">'Species prevalence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> − Underlying conditions that compromise pulmonary and systemic immune responses to inhaled <em>Aspergillus</em> species serve as risk factors for invasive pulmonary aspergillosis. Classic risk factors for invasive aspergillosis include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe and prolonged neutropenia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Receipt of high doses of glucocorticoids</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other drugs or conditions that lead to chronically impaired cellular responses (eg, immunosuppressive regimens administered to treat autoimmune diseases and to prevent organ rejection, AIDS, <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>, small molecule tyrosine kinase inhibitors) (see <a class="local">'Risk factors'</a> above)</p><p></p><p class="bulletIndent1">Other risk factors described in patients with little or no immunosuppression include, COPD (with receipt of glucocorticoids), intensive care unit admission, and certain viral infections (eg, influenza, severe acute respiratory syndrome coronavirus 2). (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Range of symptoms with pulmonary disease</strong> − Invasive aspergillosis most commonly involves the lungs  (<a class="graphic graphic_picture graphicRef57220" href="/d/graphic/57220.html" rel="external">picture 1</a>). Disease can present with a number of signs and symptoms: fever, chest pain, shortness of breath, cough, and/or hemoptysis. However, absence of symptoms should not discourage consideration of this diagnosis in the patient who has risk factors for disease since neutropenic patients frequently present with fever in the absence of localizing pulmonary symptoms. (See <a class="local">'Pulmonary aspergillosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiographic findings</strong> − Pulmonary aspergillosis typically manifests as single or multiple nodules with or without cavitation, patchy or segmental consolidation, or peribronchial infiltrates with or without tree-in-bud patterns. The radiographic progression of disease has been studied best in neutropenic patients in whom the initial findings typically include nodules that have surrounding ground-glass infiltrates (the halo sign), reflecting hemorrhage into the area surrounding the fungus  (<a class="graphic graphic_diagnosticimage graphicRef56195" href="/d/graphic/56195.html" rel="external">image 1</a>). These nodules typically enlarge, even during appropriate therapy, and may eventually cavitate, producing the air-crescent sign. Other fungal infections and <em>Pseudomonas aeruginosa</em> can show similar radiographic findings as invasive aspergillosis. (See <a class="local">'Imaging'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disseminated disease</strong> − In the presence of angioinvasive disease, <em>Aspergillus</em> spp can disseminate beyond the respiratory tract to multiple different organs, including the skin  (<a class="graphic graphic_picture graphicRef61124" href="/d/graphic/61124.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef107468" href="/d/graphic/107468.html" rel="external">picture 3</a>), brain, eyes, liver, and kidneys. Disseminated infection is associated with a very poor prognosis. (See <a class="local">'Disseminated infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other clinical manifestations</strong> − Other manifestations of invasive aspergillosis include tracheobronchitis, rhinosinusitis, brain abscess, endophthalmitis, endocarditis, and gastrointestinal disease. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> − The differential diagnosis of invasive pulmonary aspergillosis includes other angioinvasive fungal infections, such as mucormycosis, fusariosis, and scedosporiosis. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3292691525"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kieren A Marr, MD, and Daniel J Sexton, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Segal BH. Aspergillosis. N Engl J Med 2009; 360:1870.</a></li><li><a class="nounderline abstract_t">Ben-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. Br J Haematol 2010; 150:406.</a></li><li><a class="nounderline abstract_t">Balajee SA, Marr KA. Phenotypic and genotypic identification of human pathogenic aspergilli. Future Microbiol 2006; 1:435.</a></li><li><a class="nounderline abstract_t">Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.</a></li><li><a class="nounderline abstract_t">Maus MV, Lionakis MS. Infections associated with the new 'nibs and mabs' and cellular therapies. Curr Opin Infect Dis 2020; 33:281.</a></li><li><a class="nounderline abstract_t">Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood 2018; 131:1955.</a></li><li><a class="nounderline abstract_t">Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2018; 378:1107.</a></li><li><a class="nounderline abstract_t">Davis MR, Thompson GR 3rd, Patterson TF. Fungal Infections Potentiated by Biologics. Infect Dis Clin North Am 2020; 34:389.</a></li><li><a class="nounderline abstract_t">Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358.</a></li><li><a class="nounderline abstract_t">Stuehler C, Kuenzli E, Jaeger VK, et al. Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis. J Infect Dis 2015; 212:959.</a></li><li><a class="nounderline abstract_t">Camargo JF, Husain S. Immune correlates of protection in human invasive aspergillosis. Clin Infect Dis 2014; 59:569.</a></li><li><a class="nounderline abstract_t">Camargo JF, Bhimji A, Kumar D, et al. Impaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosis. PLoS One 2015; 10:e0123171.</a></li><li><a class="nounderline abstract_t">Bochud PY, Chien JW, Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766.</a></li><li><a class="nounderline abstract_t">Wójtowicz A, Gresnigt MS, Lecompte T, et al. IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation. J Infect Dis 2015; 211:1646.</a></li><li><a class="nounderline abstract_t">Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med 2014; 370:421.</a></li><li><a class="nounderline abstract_t">Wójtowicz A, Lecompte TD, Bibert S, et al. PTX3 Polymorphisms and Invasive Mold Infections After Solid Organ Transplant. Clin Infect Dis 2015; 61:619.</a></li><li><a class="nounderline abstract_t">Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 2010; 116:5394.</a></li><li><a class="nounderline abstract_t">Chai LY, de Boer MG, van der Velden WJ, et al. The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis 2011; 203:736.</a></li><li><a class="nounderline abstract_t">Iversen M, Burton CM, Vand S, et al. Aspergillus infection in lung transplant patients: incidence and prognosis. Eur J Clin Microbiol Infect Dis 2007; 26:879.</a></li><li><a class="nounderline abstract_t">Luong ML, Chaparro C, Stephenson A, et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation 2014; 97:351.</a></li><li><a class="nounderline abstract_t">Fortún J, Martín-Dávila P, Moreno S, et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8:1065.</a></li><li><a class="nounderline abstract_t">Rosenhagen M, Feldhues R, Schmidt J, et al. A risk profile for invasive aspergillosis in liver transplant recipients. Infection 2009; 37:313.</a></li><li><a class="nounderline abstract_t">Heylen L, Maertens J, Naesens M, et al. Invasive aspergillosis after kidney transplant: case-control study. Clin Infect Dis 2015; 60:1505.</a></li><li><a class="nounderline abstract_t">Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 2007; 30:782.</a></li><li><a class="nounderline abstract_t">Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007; 45:205.</a></li><li><a class="nounderline abstract_t">Wauters J, Baar I, Meersseman P, et al. Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med 2012; 38:1761.</a></li><li><a class="nounderline abstract_t">Blot SI, Taccone FS, Van den Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 2012; 186:56.</a></li><li><a class="nounderline abstract_t">Thompson Iii GR, Cornely OA, Pappas PG, et al. Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. Open Forum Infect Dis 2020; 7:ofaa242.</a></li><li><a class="nounderline abstract_t">Crum-Cianflone NF. Invasive Aspergillosis Associated With Severe Influenza Infections. Open Forum Infect Dis 2016; 3:ofw171.</a></li><li><a class="nounderline abstract_t">van de Veerdonk FL, Kolwijck E, Lestrade PP, et al. Influenza-Associated Aspergillosis in Critically Ill Patients. Am J Respir Crit Care Med 2017; 196:524.</a></li><li><a class="nounderline abstract_t">Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018; 6:782.</a></li><li><a class="nounderline abstract_t">Zhang SX, Balada-Llasat JM, Pancholi P, et al. COVID-Associated Pulmonary Aspergillosis in the United States: Is It Rare or Have We Missed the Diagnosis? J Clin Microbiol 2021; 59:e0113521.</a></li><li><a class="nounderline abstract_t">Yusuf E, Seghers L, Hoek RAS, et al. Aspergillus in Critically Ill COVID-19 Patients: A Scoping Review. J Clin Med 2021; 10.</a></li><li><a class="nounderline abstract_t">Verweij PE, Brüggemann RJM, Azoulay E, et al. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med 2021; 47:819.</a></li><li><a class="nounderline abstract_t">Fekkar A, Neofytos D, Nguyen MH, et al. COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it? Clin Microbiol Infect 2021; 27:1376.</a></li><li><a class="nounderline abstract_t">Wasylyshyn AI, Wasylyshyn GR, Linder KA, Miceli MH. COVID-19-Associated Pulmonary Aspergillosis at an Academic Medical Center in the Midwestern United States. Mycopathologia 2021; 186:499.</a></li><li><a class="nounderline abstract_t">Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 2021; 21:e149.</a></li><li><a class="nounderline abstract_t">Janssen NAF, Nyga R, Vanderbeke L, et al. Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis1. Emerg Infect Dis 2021; 27:2892.</a></li><li><a class="nounderline abstract_t">Kula BE, Clancy CJ, Hong Nguyen M, Schwartz IS. Invasive mould disease in fatal COVID-19: a systematic review of autopsies. Lancet Microbe 2021; 2:e405.</a></li><li><a class="nounderline abstract_t">Pérez-Jacoiste Asín MA, López-Medrano F, Fernández-Ruiz M, et al. Risk factors for the development of invasive aspergillosis after kidney transplantation: Systematic review and meta-analysis. Am J Transplant 2021; 21:703.</a></li><li><a class="nounderline abstract_t">Singh S, Verma N, Kanaujia R, et al. Mortality in critically ill patients with coronavirus disease 2019-associated pulmonary aspergillosis: A systematic review and meta-analysis. Mycoses 2021; 64:1015.</a></li><li><a class="nounderline abstract_t">Prattes J, Wauters J, Giacobbe DR, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect 2022; 28:580.</a></li><li><a class="nounderline abstract_t">Kanamori H, Rutala WA, Sickbert-Bennett EE, Weber DJ. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis 2015; 61:433.</a></li><li><a class="nounderline abstract_t">Horger M, Hebart H, Einsele H, et al. Initial CT manifestations of invasive pulmonary aspergillosis in 45 non-HIV immunocompromised patients: association with patient outcome? Eur J Radiol 2005; 55:437.</a></li><li><a class="nounderline abstract_t">Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006; 43:577.</a></li><li><a class="nounderline abstract_t">Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52:1144.</a></li><li><a class="nounderline abstract_t">Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15:139.</a></li><li><a class="nounderline abstract_t">Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19:253.</a></li><li><a class="nounderline abstract_t">Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41:52.</a></li><li><a class="nounderline abstract_t">Burgos A, Zaoutis TE, Dvorak CC, et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008; 121:e1286.</a></li><li><a class="nounderline abstract_t">Stanzani M, Battista G, Sassi C, et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis 2012; 54:610.</a></li><li><a class="nounderline abstract_t">Stanzani M, Sassi C, Lewis RE, et al. High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies. Clin Infect Dis 2015; 60:1603.</a></li><li><a class="nounderline abstract_t">Fortarezza F, Boscolo A, Pezzuto F, et al. Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure. Mycoses 2021; 64:1223.</a></li><li><a class="nounderline abstract_t">Permpalung N, Chiang TP, Massie AB, et al. Coronavirus Disease 2019-Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients. Clin Infect Dis 2022; 74:83.</a></li><li><a class="nounderline abstract_t">Marr KA, Platt A, Tornheim JA, et al. Aspergillosis Complicating Severe Coronavirus Disease. Emerg Infect Dis 2021; 27.</a></li><li><a class="nounderline abstract_t">Fernández-Ruiz M, Silva JT, San-Juan R, et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore) 2012; 91:261.</a></li><li><a class="nounderline abstract_t">van Assen S, Bootsma GP, Verweij PE, et al. Aspergillus tracheobronchitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26:1131.</a></li><li><a class="nounderline abstract_t">Sivak-Callcott JA, Livesley N, Nugent RA, et al. Localised invasive sino-orbital aspergillosis: characteristic features. Br J Ophthalmol 2004; 88:681.</a></li><li><a class="nounderline abstract_t">McCarthy M, Rosengart A, Schuetz AN, et al. Mold infections of the central nervous system. N Engl J Med 2014; 371:150.</a></li><li><a class="nounderline abstract_t">Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol 1994; 162:155.</a></li><li><a class="nounderline abstract_t">Levin LA, Avery R, Shore JW, et al. The spectrum of orbital aspergillosis: a clinicopathological review. Surv Ophthalmol 1996; 41:142.</a></li><li><a class="nounderline abstract_t">Riddell Iv J, McNeil SA, Johnson TM, et al. Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 2002; 81:311.</a></li><li><a class="nounderline abstract_t">Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50.</a></li><li><a class="nounderline abstract_t">El-Hamamsy I, Dürrleman N, Stevens LM, et al. Aspergillus endocarditis after cardiac surgery. Ann Thorac Surg 2005; 80:359.</a></li><li><a class="nounderline abstract_t">van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol 1998; 36:3115.</a></li><li><a class="nounderline abstract_t">Eggimann P, Chevrolet JC, Starobinski M, et al. Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature. Infection 2006; 34:333.</a></li><li><a class="nounderline abstract_t">González-Vicent M, Díaz MA, Colmenero I, et al. Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis. Transpl Infect Dis 2008; 10:193.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP, Mathur M, Chen YB, et al. Case records of the Massachusetts General Hospital. Case 13-2014. A 41-year-old man with fever and abdominal pain after stem-cell transplantation. N Engl J Med 2014; 370:1637.</a></li><li><a class="nounderline abstract_t">Kim SH, Kim MY, Hong SI, et al. Invasive Pulmonary Aspergillosis-mimicking Tuberculosis. Clin Infect Dis 2015; 61:9.</a></li></ol></div><div id="topicVersionRevision">Topic 2454 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19403905" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20618330" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17661634" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Phenotypic and genotypic identification of human pathogenic aspergilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11880955" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32657964" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Infections associated with the new 'nibs and mabs' and cellular therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29437588" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29562156" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32334987" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fungal Infections Potentiated by Biologics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393425" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25748323" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24803380" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Immune correlates of protection in human invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25835547" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Impaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18946062" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25398456" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : IL1B and DEFB1 Polymorphisms Increase Susceptibility to Invasive Mold Infection After Solid-Organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476432" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25977268" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : PTX3 Polymorphisms and Invasive Mold Infections After Solid Organ Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20807886" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21242599" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The Y238X stop codon polymorphism in the humanβ-glucan receptor dectin-1 and susceptibility to invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17874329" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Aspergillus infection in lung transplant patients: incidence and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24305637" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12424722" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk factors for invasive aspergillosis in liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19629387" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A risk profile for invasive aspergillosis in liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25681376" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Invasive aspergillosis after kidney transplant: case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17906086" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17578780" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Invasive aspergillosis in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22895826" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517788" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32754626" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27704024" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Invasive Aspergillosis Associated With Severe Influenza Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28387526" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Influenza-Associated Aspergillosis in Critically Ill Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30076119" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34288730" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : COVID-Associated Pulmonary Aspergillosis in the United States: Is It Rare or Have We Missed the Diagnosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34199528" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Aspergillus in Critically Ill COVID-19 Patients: A Scoping Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34160631" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34192575" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34143393" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : COVID-19-Associated Pulmonary Aspergillosis at an Academic Medical Center in the Midwestern United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33333012" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34519638" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34189490" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Invasive mould disease in fatal COVID-19: a systematic review of autopsies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32780498" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk factors for the development of invasive aspergillosis after kidney transplantation: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34057252" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mortality in critically ill patients with coronavirus disease 2019-associated pulmonary aspergillosis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34454093" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870328" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129254" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Initial CT manifestations of invasive pulmonary aspergillosis in 45 non-HIV immunocompromised patients: association with patient outcome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886149" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21467021" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996135" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134220" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15937763" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450871" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22173235" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25722200" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34157166" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33693551" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Coronavirus Disease 2019-Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33084566" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Aspergillosis Complicating Severe Coronavirus Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22932790" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Aspergillus tracheobronchitis: report of 8 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11108318" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Aspergillus tracheobronchitis after allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15090423" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Localised invasive sino-orbital aspergillosis: characteristic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006721" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mold infections of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8273655" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8890440" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The spectrum of orbital aspergillosis: a clinicopathological review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12169886" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11118386" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fungal endocarditis: evidence in the world literature, 1965-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15975413" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Aspergillus endocarditis after cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9774549" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cutaneous aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17180588" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18069930" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24758620" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Case records of the Massachusetts General Hospital. Case 13-2014. A 41-year-old man with fever and abdominal pain after stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25778752" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Invasive Pulmonary Aspergillosis-mimicking Tuberculosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
